(MedPage Today) — BARCELONA — A drug targeting immunoglobulin G (IgG) currently approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP) now looks like it could take the rheumatology field by storm, if phase…
Source link : https://www.medpagetoday.com/meetingcoverage/eular/116027
Author :
Publish date : 2025-06-11 21:40:00
Copyright for syndicated content belongs to the linked Source.
